Promore Pharma
STOCKHOLM, SWEDEN / ACCESSWIRE / December 08, 2021 / Promore Pharma (STO:PROMO) (FRA:8T0)
STOCKHOLM, 8 December 2021 - Promore Pharma AB, a Swedish biopharmaceutical developer of therapeutic peptides, have announced today that the company has received a granted patent in the US for the use of the candidate drug ropocamptide (LL-37) for the treatment of chronic wounds.
Promore Pharma's product candidate ropocamptide is undergoing development for treatments aimed at healing venous leg ulcers. Promore Pharma announced today that they have been granted another patent in the United States regarding its substance ropocamptide. The patent protects the treatment of chronic wounds such as venous leg ulcers and diabetic foot ulcers by treating patients with a pharmaceutical formulation containing ropocamptide in therapeutically effective doses. The patent period extends until at least November 2034, with the possibilities of further patent extension.
"We are now taking another step in our strategic work to create far-reaching intellectual property protection for our innovative prescription drug for the treatment of various types of hard-healing wounds," said Jonas Ekblom, CEO of Promore Pharma. "Overall, we now have strong and extensive patent protection for ropocamptide in the world's largest pharmaceutical market, which will be of paramount importance when our product reaches the market," he continued.
Within the ropocamptide project for the treatment of venous leg ulcers, which is the most common type of chronic leg ulcers, a clinical Phase II trial, the HEAL LL-37 study, was concluded during the autumn 2020. The most important finding from that clinical trial was that ropocamptide shows a significant effect in the patient subgroup with large wounds (≥10 cm2). The company assesses that there are at least 1 million patients in North America, the EU, the UK, and Japan with large venous leg ulcers, which implies an annual addressable market of approx. SEK 30 billion.
For additional information, please contact
Jonas Ekblom, CEO
Phone: [+46] 736 777 540
E-mail: jonas.ekblom@promorepharma.com
Erik Magnusson, CFO
Phone: [+46] 708 565 245
E-mail: erik.magnusson@promorepharma.com
Promore Pharmas Certified Adviser is Erik Penser Bank
Tel: [+46] 8-463 83 00
E-mail: certifiedadviser@penser.se
Promore Pharma in brief
Promore Pharma is a biopharmaceutical company specialized in the development of therapeutic peptides. The company's aim is to develop first-in-category pharmaceuticals for indications with high unmet medical needs, where very few efficacious prescription pharmaceuticals are available. Promore Pharma's two projects are undergoing clinical development and have a very strong safety profile since the products are based on endogeneous substances that are administered locally. The leading project, ensereptide (PXL01), that will be used for prevention of post-surgical scarring, is being prepared for a clinical phase II-trial if the peptide can prevent the formation of unesthetical scars on the skin. Ropocamptide (LL-37) has recently been evaluated in a clinical phase IIb study with positive results in patients with venous leg ulcers (VLUs). The product candidates can also be deployed for other indications, such as preventing unfavorable tissue attachments (adhesions) after different kinds of surgical procedures and treatment of diabetic foot ulcers. The company is listed on Nasdaq First North Growth Market.
Attachments
Promore Pharma granted US patent regarding treatment of chronic wounds
SOURCE: Promore Pharma
View source version on accesswire.com:
https://www.accesswire.com/676500/Promore-Pharma-Granted-US-Patent-Regarding-Treatment-Of-Chronic-Wounds
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
From Office Flirtation to Bestselling Romance Novel: The Story Behind Patricia Dlamini's New Book Launch5.7.2025 00:00:00 CEST | Press release
From office flirtation to bestselling romance novel, the journey of author Patricia Dlamini captures the imagination of readers and aspiring writers alike. Her latest book, 'The Competitor's Kiss: When Rivalry Turns to Romance, Who Really Wins?,' takes inspiration from her own experiences in the corporate world, intertwining personal anecdotes with imaginative storytelling to create a captivating narrative that resonates with many. CAPE TOWN, ZA / ACCESS Newswire / July 4, 2025 / The story follows two colleagues who develop a romantic relationship amidst the challenges of office politics and career aspirations. As the protagonists navigate their feelings and professional lives, readers are treated to an engaging exploration of love, ambition, and the complexities of workplace dynamics. Dlamini's ability to blend humor with heartfelt moments allows the narrative to stand out in a crowded genre.Amazon.com: The Competitor's Kiss: When Rivalry Turns to Romance, Who Really Wins? Checkout Bo
Sweden, the Czech Republic, and Greece Crowned Champions of Harm Reduction in Brussels3.7.2025 06:00:00 CEST | Press release
BRUSSELS, BE / ACCESS Newswire / July 3, 2025 / Brussels transformed into a Champions League pitch for tobacco harm reduction as the World Vapers' Alliance (WVA) honoured Sweden, the Czech Republic, and Greece with the "Champions of Change" trophy for their outstanding progress in cutting smoking rates. The ceremony, staged in front of the European Parliament, shone a spotlight on the countries leading Europe's fight against smoking-while EU officials looked on from the sidelines. WVA Director Michael Landl, presenting the awards, remarked, "The EU is stuck in a cycle of prohibition and continues to overlook the evidence that's saving lives. Instead of embracing proven solutions, Brussels is making it harder for smokers to quit." Sweden led the celebrations, having become the world's first officially smoke-free nation, with just 4.5% of Swedish-born adults smoking-five times lower than the EU average and 16 years ahead of the EU's own goal. The Czech Republic and Greece were also recog
Fineqia Issues Bitcoin Yield ETP via DeFi; Yield Compounds Investors' BTC Holdings2.7.2025 17:00:00 CEST | Press release
LONDON, UK / ACCESS Newswire / July 2, 2025 / Fineqia International Inc. (CSE:FNQ)(OTC:FNQQF) (Frankfurt:FNQA), a digital asset and investment business, announces the Fineqia Bitcoin Yield Exchange Traded Product (ETP) (Ticker: YBTC, ISIN: LI1444931821), a listed product that enables investors to garner additional Bitcoin while holding it. YBTC targets an annual yield of 6% via decentralised finance (DeFi) activities on the blockchain. YBTC automatically converts this yield into Bitcoin (BTC), increasing an investor's BTC holdings without requiring any additional capital. Listed on the Vienna Stock Exchange (Wiener Börse), it is the first regulated, exchange-traded instrument in the world to provide BTC yield from DeFi protocols. The product is available for institutional and retail investors. "With YBTC, we've transformed Bitcoin from a store of value into a yield-generating digital asset," said Bundeep Singh Rangar, chief executive officer of Fineqia. "It allows investors to earn mor
Global Sports Brand U.S. Polo Assn. Launches in Brazil With Grupo Pasquini2.7.2025 13:15:00 CEST | Press release
WEST PALM BEACH, FL AND SAO PAULO, BRAZIL / ACCESS Newswire / July 2, 2025 / U.S. Polo Assn., the official brand of the United States Polo Association (USPA), is proud to announce its launch in the Brazilian market in partnership with Grupo Pasquini, a leading player in the country's fashion industry. This expansion reinforces the global, sport-inspired brand's presence in Latin America and further supports U.S. Polo Assn.'s strategic growth plan to reach new consumers around the world.U.S. Polo Assn. As U.S. Polo Assn. continues to expand its multi-billion-dollar global presence, Brazil marks an exciting new chapter in the brand's international journey. With its vibrant retail landscape and deep-rooted passion for lifestyle fashion, Brazil offers a natural fit for U.S. Polo Assn.'s authentic connection to the sport of polo. The debut collection in Brazil will showcase timeless, versatile styles across both menswear and womenswear, designed to honor the heritage of the sport while embr
Picktan Capital to Post Record Q2 Amid Market Buzz Over Possible IPO1.7.2025 20:55:00 CEST | Press release
LONDON, UK / ACCESS Newswire / July 1, 2025 / Picktan Capital, a London-headquartered wealth management firm managing over $7 billion in client assets globally, is attracting attention amid growing speculation about a potential public listing. The firm is on track to report its strongest quarterly performance to date, marking a significant milestone in its global growth strategy. With a strong emphasis on emerging technologies and disciplined capital deployment, Picktan Capital's momentum in 2024 has captured the interest of both investors and analysts. Picktan's second-quarter performance reflects a maturing investment approach grounded in both innovation and long-term value. The firm's activity across pivotal sectors, notably aerospace innovation, AI development, and satellite communications, has translated into meaningful gains and reinforced confidence in its forward strategy. Rather than chasing trends, Picktan has concentrated on sectors undergoing structural transformation. Its
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom